Table 5 Comparison between the results obtained and their counterparts from previous studies.
LO, % | BD, % | CC, % | Setting time | Compressive strength at 28 d (MPa) | Shielding against gamma | Shielding against neutrons | Ref. |
|---|---|---|---|---|---|---|---|
0.05–1 | – | – | Acceptable dosage for compressive enhancing is 0.25 | Increases up to 0.05 | – | – | |
– | 1–5 | – | Increases with dose increasing. As all proportions exceed the specification limits. | Decreases with dose increasing | Enhancing with dose increasing | Enhancing with dose increasing | |
– | 0–0.5 | – | Delayed by increasing the dose | Enhancing with dose increasing alter age | - | – | |
5 | – | – | Excessively delayed due to overdose by more than 2% | Increased up to 2 | Enhancing with dose 5 | – | |
0.1–0.5 | – | – | Increases with dose exceeding 0.2 | Increases up to 0.2 | Enhancing with dose 0.2 | Enhancing with dose 0.2 | |
1.5 | – | 0.5 | Reduced by 20 min. | Increased by 81% | High | – | Current study |
– | 0.5 | 0.5 | Reduced by 36 min. | Increased by 5% | – | High |
